Immune responses following third COVID-19 vaccination are reduced in patients with hematologic malignancies compared to patients with solid cancer

Annika Fendler  
Cancer Dynamics Laboratory, The Francis Crick Institute

Scott T.C. Shepherd  
Cancer Dynamics Laboratory, The Francis Crick Institute

Lewis Au  
Cancer Dynamics Laboratory, The Francis Crick Institute

Katalin A. Wilkinson  
Tuberculosis Laboratory, The Francis Crick Institute

Mary Wu  
High Throughput Screening Laboratory, The Francis Crick Institute

Andreas M. Schmitt  
Skin and Renal Units, The Royal Marsden NHS Foundation Trust

Zayd Tippu  
Cancer Dynamics Laboratory, The Francis Crick Institute

Sheima Farag  
Skin and Renal Units, The Royal Marsden NHS Foundation Trust

Aljosja Rogiers  
Skin and Renal Units, The Royal Marsden NHS Foundation Trust

Ruth Harvey  
Worldwide Influenza Centre, The Francis Crick Institute

Eleanor Carlyle  
Skin and Renal Units, The Royal Marsden NHS Foundation Trust

Kim Edmonds  
Skin and Renal Units, The Royal Marsden NHS Foundation Trust

Lyra Del Rosario  
Skin and Renal Units, The Royal Marsden NHS Foundation Trust

Karla Lingard
Skin and Renal Units, The Royal Marsden NHS Foundation Trust

Mary Mangwende  
Skin and Renal Units, The Royal Marsden NHS Foundation Trust

Lucy Holt  
Skin and Renal Units, The Royal Marsden NHS Foundation Trust

Hamid Ahmod  
Skin and Renal Units, The Royal Marsden NHS Foundation Trust

Justine Korteweg  
Skin and Renal Units, The Royal Marsden NHS Foundation Trust

Tara Foley  
Skin and Renal Units, The Royal Marsden NHS Foundation Trust

Taja Barber  
Cancer Dynamics Laboratory, The Francis Crick Institute

Andrea Emslie-Henry  
Cancer Dynamics Laboratory, The Francis Crick Institute

Niamh Caulfield-Lynch  
Cancer Dynamics Laboratory, The Francis Crick Institute

Fiona Byrne  
Cancer Dynamics Laboratory, The Francis Crick Institute

Benjamin Shum  
Cancer Dynamics Laboratory, The Francis Crick Institute

Camille L. Gerard  
Cancer Dynamics Laboratory, The Francis Crick Institute

Daqi Deng  
Cancer Dynamics Laboratory, The Francis Crick Institute

Svend Kjaer  
Structural Biology of Disease Processes Laboratory, The Francis Crick Institute, London

Ok-Ryul Song  
High Throughput Screening Laboratory, The Francis Crick Institute

Christophe Queval  
High Throughput Screening Laboratory, The Francis Crick Institute

Caitlin Kavanagh  
High Throughput Screening Laboratory, The Francis Crick Institute

Emma C. Wall  
University College London Hospitals NHS Foundation Trust Biomedical Research Centre

Edward J. Carr  
Cell Biology of Infection Laboratory, The Francis Crick Institute

Sina Namjou  
Safety, Health & Sustainability, The Francis Crick Institute
Simon Caidan  
Safety, Health & Sustainability, The Francis Crick Institute

Mike Gavrielidis  
Scientific Computing Scientific Technology Platform, The Francis Crick Institute

James McRae  
Metabolomics Scientific Technology Platform, The Francis Crick Institute

Gavin Kelly  
Department of Bioinformatics and Biostatistics, The Francis Crick Institute

Kema Peat  
Skin and Renal Units, The Royal Marsden NHS Foundation Trust

Denise Kelly  
Skin and Renal Units, The Royal Marsden NHS Foundation Trust

Aida Murra  
Skin and Renal Units, The Royal Marsden NHS Foundation Trust

Kayleigh Kelly  
Skin and Renal Units, The Royal Marsden NHS Foundation Trust

Molly O'Flaherty  
Skin and Renal Units, The Royal Marsden NHS Foundation Trust

Robyn L. Shea  
Department of Pathology, The Royal Marsden NHS Foundation Trust

Gail Gardner  
Translational Cancer Biochemistry Laboratory, The Institute of Cancer Research

Darren Murray  
Translational Cancer Biochemistry Laboratory, The Institute of Cancer Research

Nadia Yousaf  
Lung Unit, The Royal Marsden NHS Foundation Trust

Shaman Jhanji  
Anaesthetics, Perioperative Medicine and Pain Department, The Royal Marsden NHS Foundation Trust, London

Nicholas Van As  
Clinical Oncology Unit, The Royal Marsden NHS Foundation Trust

Kate Young  
Skin and Renal Units, The Royal Marsden NHS Foundation Trust

Andre J.S. Furness  
Skin and Renal Units, The Royal Marsden NHS Foundation Trust

Lisa Pickering  
Skin and Renal Units, The Royal Marsden NHS Foundation Trust

Rupert Beale  
Cell Biology of Infection Laboratory, The Francis Crick Institute
Charles Swanton  
Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute

Sonia Ghandi  
Neurodegeneration Biology Laboratory, The Francis Crick Institute

Steve Gamblin  
Structural Biology of Disease Processes Laboratory, The Francis Crick Institute

David L.V. Bauer  
RNA Virus Replication Laboratory, The Francis Crick Institute,

George Kassiotis  
Retroviral Immunology Laboratory, The Francis Crick Institute

Michael Howell  
High Throughput Screening Laboratory, The Francis Crick Institute

Emma Nicholson  
Haemato-oncology Unit, The Royal Marsden NHS Foundation Trust

Robert J. Wilkinson  
Tuberculosis Laboratory, The Francis Crick Institute

James Larkin  
Skin and Renal Units, The Royal Marsden NHS Foundation Trust

Samra Turajlic (✉ samra.turajlic@crick.ac.uk)  
Cancer Dynamics Laboratory, The Francis Crick Institute

Research Article

**Keywords:** COVID-19, solid cancer, hematologic cancer, vaccine, booster

**Posted Date:** December 22nd, 2021

**DOI:** https://doi.org/10.21203/rs.3.rs-1191603/v1

**License:** ☕️ This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Not all patients with cancer, in particular those with hematologic malignancies, develop functional immunity against SARS-CoV-2 variants of concern (VOC) following COVID-19 vaccines. Durability of vaccine-induced immunity after two doses and the impact of a third dose were evaluated in CAPTURE (NCT03226886), a longitudinal prospective cohort study of vaccine responses in patients with cancer. In evaluating 316 patients, at a median of 111 days following two doses of either BNT16b2 or ChadOX, we observed a time-dependent decline in neutralising antibody titres (NAbT) in a proportion of patients, where NAbTs became undetectable against Delta and Beta in 17% and 15% of patients, respectively. Vaccine-induced T cell responses declined in 44% of patients. Patients with breakthrough infections following two vaccines doses were characterised by absent/low NAbT to Delta prior to infection. Administration of the third vaccine dose boosted NAb responses against VOC in the majority of patients with cancer, especially those with solid cancer. In patients with hematologic malignancies who had undetectable NAbT against Delta after two vaccine doses, 54% did not develop NAb against both Beta and Delta following the third dose. Third vaccine dose boosted T cell responses were boosted in patients with both solid and hematologic malignancies. These results provide critical information on vaccine responses in patients with cancer, especially against VOCs and support widespread access to a third COVID-19 vaccination in this patient group.

Full Text

Patients with cancer are at higher risk of severe COVID-19 (Grivas et al., 2021; Kuderer et al., 2020), and are currently prioritized for a third COVID-19 vaccine dose globally. Humoral and cellular immune responses are detected after two primary COVID-19 vaccine doses in most patients with cancer (Ehmsen et al., 2021; Fendler et al., 2021; Oosting et al.), although neutralising responses are reduced against variants of concern (VOC). Neutralising responses are frequently impaired in patients with hematologic malignancies especially those receiving B cell-depleting therapies (Ehmsen et al., 2021; Fendler et al., 2021; Thakkar et al.). As neutralising antibody (NAb) responses directly associate with vaccine efficacy (Gilbert Peter et al.; Khoury et al., 2021), these patients without a neutralising response are at higher risk of breakthrough infections (Hippisley-Cox et al., 2021). Here, we report follow-up results from CAPTURE (NCT03226886), a longitudinal, prospective cohort study of vaccine response in patients with cancer, relative to the duration of response after two doses of either BNT162b2 (Pfizer) or ChAdOx1 (AstraZeneca); and following third vaccination with BNT162b2. We present data on NAb and T cell responses against whole live virus, including wildtype SARS-CoV-2 (WT), Beta, and Delta VOC. We specifically evaluated responses to Beta and Delta given their known immune-evasive capacity.

We assessed the durability of NAb responses in 353 patients [77% (n=271) with solid, and 23% (n=82) with hematologic malignancies], (Table S1), following two doses of COVID-19 vaccine [72% (n=255) ChAdOx1, 28% (n=98) BNT162b2]. NAb against WT SARS-CoV-2 were undetectable 14-28 days and up to 110 days (range 84-153) following the second dose in 4% (n=12) of patients with solid, and 30% (n=25) of patients with hematologic malignancies. In those who initially had detectable post-second dose
NAb against WT (n=316; 71% against Beta, and 62% against Delta), we observed a time-dependent decline in NAb titres (NAbT) during follow up (median of 111 days, range: 37-252 day after the second vaccine dose) (Figure S1A). After an initial response to two vaccine doses, in patients with solid cancer (n=259), 1% (n=3) had undetectable NAbs against WT, 17% (n=43) against Beta, and 18% (n=47) against Delta; in patients with hematologic malignancies (n=57), 7% (n=4) had undetectable NAbT against WT, 9% (n=5) against Beta, and 16% (n=9) against Delta. The proportions of those with waning NAb did not differ significantly between patients with solid or hematologic malignancies, apart from WT (Chi$^2$ test: WT, p = 0.02, Beta, p = 0.16, Delta, p = 0.67).

We previously reported that T cell responses, measured 14-28 days after the second dose, are comparable between patients with solid and hematologic malignancies and can also be detected in those without NAb responses (Fendler et al., 2021). During follow up [median of 93 days (range: 63-171 days) after the second dose], we evaluated T cell responses in 55 patients. Patients without a detectable T cell response following the second dose remained negative. In those with an initial response (n=43 with solid and n=12 with hematologic malignancies) (Figure 1SB), it was maintained in 49% (n=21) of patients with solid and 42% (n=5) with hematologic malignancies (Wilcoxon signed rank test, p = 0.56).

During the course of routine clinical care, 8 CAPTURE participants (n=7 with solid and n=1 with hematological malignancy) were diagnosed with SARS-COV-2 following two vaccine doses between July and October 2021 [median time between second vaccine dose and infection: 118 days (range: 59-173)], likely to be caused by the Delta variant that was dominant in the U.K. at that time. The symptoms were either mild [n=7 patients; WHO severity score 2-3; fever (n=5), coryza (n=4), anosmia (n=4) and cough (n=3)] or absent (n=1 patient), not requiring hospital care, and all patients recovered. We evaluated immune responses prior to infection following two vaccine doses; while all patients had detectable NAbT against WT SARS-CoV-2, only one had detectable NAbT against Delta. Following infection, all patients mounted a detectable neutralising response to Delta (Figure S1C). T cell responses were evaluable in 5 patients prior to infection and in 7 patients following infection. While only 1/5 patients had detectable T cell responses to WT prior to infection, 5/7 had a detectable T cell response following infection, including 2/4 patients that had undetectable T cell responses before infection (Figure S1D).

We next evaluated 199 cancer patients [n=115 (58%) with solid cancer] who received a third vaccine dose per UK guidelines. Patients who tested positive for SARS-CoV-2 by RT-PCR between second and third dose were excluded from this analysis. All patients received a third dose of BNT162b2, following two doses of either BNT162b2 (33%) or ChAdOx1 (67%) (Table S1). The median time between second and third vaccine dose was 176 days (range 65-274 days), and immune responses were measured at a median of 23 days after the third dose (range: 11-47 days). Prior to third dose, 88% (n=176) had detectable NAb against WT, but given the dominance of Delta, we considered all patients with undetectable NAb against Delta as ‘non-responders’ to two doses [51% (n=102); 43% (n=50) of solid cancer and 62% (n=52) of hematologic malignancy] (Table S1).
Considering non-responders to Delta after two vaccine doses, in solid cancer patients \((n=50)\), following the third dose 94\% \((n=47)\) had detectable NAb against Delta, and 88\% \((n=44)\) against Beta (Figure S1E); in patients with hematologic malignancy \((n=52)\), following the third dose 54\% \((n=28)\) had detectable NAb against Delta, and 54\% \((n=28)\) against Beta. The proportion of those with detectable NAb after third dose was significantly higher in patients with solid malignancies (Chi\(^2\) test: Beta; \(p = 0.0002\), Delta; \(p < 0.0001\)). Finally, following the third dose we observed an increase in median NAbT against all variants in initial responders (patients with detectable NAb against Delta after two vaccine doses).

Our data indicate that a third vaccine dose can generate NAb in patients who are non-responders following two doses, and further boosts NAbT against VOCs in responders. However, the proportion of patients with hematologic malignancies with undetectable NAbT against Delta following the third vaccine dose remains significant (46\%).

Multivariable binary regression analysis shows that the presence of hematologic malignancy was significantly associated with undetectable NAb against Beta or Delta after the third dose (variables included: cancer type, age, primary vaccine type, and sex). Considering patients with hematologic malignancies in a further multivariate analysis (see Table S1 for included variables), primary vaccination with BNT162b2 \((n=17)\) vs ChAdOx1 \((n=35)\) was significantly associated with lack of neutralising responses against Beta and Delta [BNT162b2: Delta 29\% \((n=5)\), Beta, 35\% \((n=6)\); ChAdOx1: Delta, 66\% \((n=23)\); Beta, 63\% \((n=22)\)], suggesting benefit of the heterologous vaccination approach. Following the third vaccine dose, in patients who had received anti-CD20 in the 12 months prior to the first vaccine dose, 1/6 had detectable NAbT against Delta and 2/6 against Beta. In the group of patients who commenced anti-CD20 therapy between the second and third dose 3/4 patients had detectable NAbT against Delta and Beta following the third dose.

Following stimulation with WT, Beta, and Delta spike-specific peptide pools T cell responses were measured by IFN-\(\gamma\) ELISPOT (Fendler et al., 2021) in a subset of 48 patients [69\% \((n=33)\) solid cancer] representative of the cohort that received a third dose. Prior to third dose, 33\% \((n=11)\) of patients with solid and 40\% \((n=6)\) of patients with hematologic malignancies had detectable T cell responses. Following the third vaccine dose, this rose to 73\% \((n=24)\) and 73\% \((n=11)\), respectively. The number of SFU/10\(^6\) was significantly increased after the third dose relative to post-second dose (Figure S1F).

Our data show a third dose of COVID-19 vaccine boosts NAb responses in patients with cancer including those that had undetectable NAbT following two vaccine doses, or where NAbT waned. We found that NAbT were higher in patients who received two doses of ChAdOx1 and a third dose of BNT162b2 compared to three doses of BNT162b2. Further, we show that T cell responses are amplified following third vaccine dose likely offering additional protection especially in individuals with low or absent neutralising responses. Encouragingly, the proportion of patients with solid cancer that had detectable responses after third vaccination is high and comparable to individuals without cancer. In contrast, a substantial proportion of patients with hematologic malignancies still had undetectable neutralising responses following third vaccine dose, especially against VOCs and may remain at risk of breakthrough
infection. These findings are particularly pertinent given reports of reduced vaccine efficacy and NAb activity against the emerging Omicron VOC compared to Delta (Cele et al., 2021).

**Declarations**

Declaration of interests

The authors declare no competing interests.

**References**

1. Cele, S., Jackson, L., Khan, K., Khoury, D.S., Moyo-Gwete, T., Tegally, H., Scheepers, C., Amoako, D., Karim, F., Bernstein, M., et al. (2021). SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv, 2021.12.2020.21267417.

2. Ehmsen, S., Asmussen, A., Jeppesen, S.S., Nilsson, A.C., Østerlev, S., Vestergaard, H., Justesen, U.S., Johansen, I.S., Frederiksen, H., and Ditzel, H.J. (2021). Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer. Cancer Cell 39, 1034–1036.

3. Fendler, A., Shepherd, S.T.C., Au, L., Wilkinson, K.A., Wu, M., Byrne, F., Cerrone, M., Schmitt, A.M., Joharatnam-Hogan, N., Shum, B., et al. (2021). Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nature Cancer.

4. Gilbert Peter, B., Montefiori David, C., McDermott Adrian, B., Fong, Y., Benkeser, D., Deng, W., Zhou, H., Houchens Christopher, R., Martins, K., Jayashankar, L., et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 0, eab3435.

5. Grivas, P., Khaki, A.R., Wise-Draper, T.M., French, B., Hennessy, C., Hsu, C.Y., Shyr, Y., Li, X., Choueiri, T.K., Painter, C.A., et al. (2021). Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Annals of Oncology 32, 787–800.

6. Hippisley-Cox, J., Coupland, C.A., Mehta, N., Keogh, R.H., Diaz-Ordaz, K., Khunti, K., Lyons, R.A., Kee, F., Sheikh, A., Rahman, S., et al. (2021). Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. BMJ 374, n2244.

7. Khoury, D.S., Cromer, D., Reynaldi, A., Schlub, T.E., Wheatley, A.K., Juno, J.A., Subbarao, K., Kent, S.J., Triccas, J.A., and Davenport, M.P. (2021). Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine 27, 1205–1211.

8. Kuderer, N.M., Choueiri, T.K., Shah, D.P., Shyr, Y., Rubinstein, S.M., Rivera, D.R., Shete, S., Hsu, C.Y., Desai, A., de Lima Lopes, G., Jr., et al. (2020). Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 395, 1907-1918.
9. Oosting, S.F., van der Veldt, A.A.M., GeurtsvanKessel, C.H., Fehrmann, R.S.N., van Binnendijk, R.S., Dingemans, A.-M.C., Smit, E.F., Hiltermann, T.J.N., den Hartog, G., Jalving, M., et al. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. The Lancet Oncology.

10. Thakkar, A., Gonzalez-Lugo, J.D., Goradia, N., Gali, R., Shapiro, L.C., Pradhan, K., Rahman, S., Kim, S.Y., Ko, B., Sica, R.A., et al. Seroconversion rates following COVID-19 vaccination amongst patients with cancer. Cancer Cell.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- 20211218SupplementaryDataFileTurajlicclean.pdf